Uluru Inc (ULUR) 0.0360 $ULUR ULURU Inc. Report
Post# of 273242
Posted On: 09/19/2016 7:09:19 AM
Uluru Inc (ULUR) 0.0360 $ULUR
ULURU Inc. Reports Financial Results For Second Quarter 2016
PR Newswire - Tue Aug 16, 7:30AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the second quarter ended June 30, 2016 and provided a review of its operating activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ending June 30, 2016
PR Newswire - Wed Aug 10, 2:01PM CDT
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ending June 30, 2016 financial results and to provide a general business update on August 16, 2016 at 9:00 a.m. Eastern Time.
ULURU Inc. Signs Cooperation Agreement For Japan
PR Newswire - Thu Jun 02, 3:30PM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development and commercialization of a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc(TM) transmucosal delivery system, is pleased to provide an update on the Company's corporate and business operational activities.
ULURU Inc. Reports Financial Results For First Quarter 2016
PR Newswire - Tue May 17, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the first quarter ended March 31, 2016 and provided a review of its operating activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ending March 31, 2016
PR Newswire - Thu May 12, 9:56AM CDT
ADDISON, Texas, May 12, 2016 /PRNewswire/-- ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the first quarter ending March 31, 2016 financial results and to provide a general business update on Tuesday, May 17, 2016 at 9:00 a.m. Eastern Time.
ULURU Inc. To Attend 26th Annual European Wound Management Association Conference
PR Newswire - Tue May 10, 11:21AM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development and commercialization of (i) a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and (ii) mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc(TM) transmucosal delivery system, today announced the ULURU Inc. will be presenting and demonstrating Altrazeal® at the 26th Annual European Wound Management Association conference ("EWMA"
being held between May 11 and May 13, 2016 in Bremen, Germany. EWMA anticipates attracting approximately 5,000 to 7,000 attendees from across Europe and around the world. The Company previously presented and demonstrated Altrazeal® at the EWMA conference held in Madrid in 2014 and generated substantial interest from practitioners and distributors alike.
ULURU Inc. Announces
PR Newswire - Mon Dec 28, 6:30AM CST
ULURU Inc. (OTCQB: ULUR).
ULURU Inc. Announces Resignation Of Director
PR Newswire - Wed Dec 02, 3:01PM CST
ULURU Inc. (OTCQB: ULUR) today announced the resignation of Jeffrey B. Davis as a Director of the Company, effective December 1, 2015.
ULURU Inc. Announces Resignation Of Chief Executive Officer
PR Newswire - Fri Nov 20, 7:54AM CST
ULURU Inc. (OTCQB: ULUR) today announced the resignation of Kerry P. Gray as President and Chief Executive Officer of the Company effective immediately.
ULURU INC. Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Nov 17, 7:00AM CST
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the third quarter ended September 30, 2015 and provided a review of its business activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter 2015
PR Newswire - Wed Nov 11, 9:29AM CST
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the third quarter ending September 30, 2015 financial results and to provide a general business update on November 17, 2015 at 9:00 a.m. Eastern Time.
Global Collagens Pipeline Review 2015 Now Available
M2 - Thu Oct 08, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4tfqz7/collagens) has announced the addition of the "Collagens - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Collagens pipeline products. Scope - Extensive coverage of the Collagens under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Collagens and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Collagens - Pipeline Products under Development by Companies 5 Collagens Companies and Product Overview 6 Collagens- Recent Developments 7 Appendix Companies Mentioned - Advanced Medical Solutions Group plc - AGAM Biological Products - Alliqua BioMedical, Inc. - botiss dental GmbH - CollPlant Ltd. - Conversion Energy Enterprises - Covalon Technologies Ltd. - EternoGen, LLC - Holista CollTech Limited - Innocoll Technologies Limited - Jellagen Pty Ltd - Kyeron BV - Medtronic plc - Nanotherapeutics, Inc. - PlasMedica Technologies Limited - Shire Plc - Taxus Cardium Pharmaceuticals Group Inc. - ULURU Inc. For more information visit http://www.researchandmarkets.com/research/4tfqz7/collagens
MDT: 86.01 (+0.35), SHPG: 200.60 (+4.11)
ULURU Inc. To Raise $1,550,000 In Private Placement
PR Newswire - Fri Sep 11, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the signing of a definitive agreement to sell an aggregate of 4,079,539 shares of its common stock at a price per share of $0.38 to a group of European investors, which is expected to result in gross proceeds of $1,550,225. Under the terms of the agreement, the Company is obligated to file a registration statement registering the re-sale of the purchased shares, and the transaction will close promptly following the effectiveness of the registration statement. Such registration statement is required to be filed with the Securities and Exchange Commission promptly and the Company will use its best efforts to have it declared effective at the earliest possible date. The net proceeds of the private placement after expenses is estimated to be approximately $1,350,000.
ULURU Inc. Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 17, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the second quarter ended June 30, 2015 and provided a review of its business activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter 2015
PR Newswire - Wed Aug 05, 4:37PM CDT
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ending June 30, 2015 financial results and to provide a general business update on August 17, 2015 at 9:00 a.m. Eastern Time.
ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors
PR Newswire - Tue Jul 28, 7:30AM CDT
ULURU Inc. (OTCQB: ULUR) announced today the schedule for the 2015 Annual Meeting of Stockholders and the appointment of Bradley J. Sacks to the Company's Board of Directors.
ULURU Inc. Announces Interim Pharmacoeconomic Data
PR Newswire - Tue Jun 09, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) announced today interim results of a pharmacoeconomic evaluation being conducted in Europe.
ULURU Inc. Reports First Quarter 2015 Financial Results
PR Newswire - Mon May 18, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the first quarter ended March 31, 2015 and provided a review of its operating activities.
ULURU Inc. Announces The Acquisition Of Altrazeal Trading GmbH
PR Newswire - Thu May 14, 8:35AM CDT
ULURU Inc. (OTCQB: ULUR) announced it will be acquiring the 75% ownership of Altrazeal Trading GmbH not currently owned by the Company. The company was granted the option pursuant to a Shareholders Agreement dated January 11, 2012, to acquire the remaining ownership for a predetermined valuation. Altrazeal Trading GmbH was established to commercialize Altrazeal, our proprietary wound care product, in Europe, the Middle East, and Australia/New Zealand.
ULURU Inc. Reports Financial Results For Second Quarter 2016
PR Newswire - Tue Aug 16, 7:30AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the second quarter ended June 30, 2016 and provided a review of its operating activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ending June 30, 2016
PR Newswire - Wed Aug 10, 2:01PM CDT
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ending June 30, 2016 financial results and to provide a general business update on August 16, 2016 at 9:00 a.m. Eastern Time.
ULURU Inc. Signs Cooperation Agreement For Japan
PR Newswire - Thu Jun 02, 3:30PM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development and commercialization of a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc(TM) transmucosal delivery system, is pleased to provide an update on the Company's corporate and business operational activities.
ULURU Inc. Reports Financial Results For First Quarter 2016
PR Newswire - Tue May 17, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the first quarter ended March 31, 2016 and provided a review of its operating activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ending March 31, 2016
PR Newswire - Thu May 12, 9:56AM CDT
ADDISON, Texas, May 12, 2016 /PRNewswire/-- ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the first quarter ending March 31, 2016 financial results and to provide a general business update on Tuesday, May 17, 2016 at 9:00 a.m. Eastern Time.
ULURU Inc. To Attend 26th Annual European Wound Management Association Conference
PR Newswire - Tue May 10, 11:21AM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development and commercialization of (i) a portfolio of wound care and wound management products utilizing its innovative Nanoflex® Aggregate technology, and (ii) mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc(TM) transmucosal delivery system, today announced the ULURU Inc. will be presenting and demonstrating Altrazeal® at the 26th Annual European Wound Management Association conference ("EWMA"
being held between May 11 and May 13, 2016 in Bremen, Germany. EWMA anticipates attracting approximately 5,000 to 7,000 attendees from across Europe and around the world. The Company previously presented and demonstrated Altrazeal® at the EWMA conference held in Madrid in 2014 and generated substantial interest from practitioners and distributors alike. ULURU Inc. Announces
PR Newswire - Mon Dec 28, 6:30AM CST
ULURU Inc. (OTCQB: ULUR).
ULURU Inc. Announces Resignation Of Director
PR Newswire - Wed Dec 02, 3:01PM CST
ULURU Inc. (OTCQB: ULUR) today announced the resignation of Jeffrey B. Davis as a Director of the Company, effective December 1, 2015.
ULURU Inc. Announces Resignation Of Chief Executive Officer
PR Newswire - Fri Nov 20, 7:54AM CST
ULURU Inc. (OTCQB: ULUR) today announced the resignation of Kerry P. Gray as President and Chief Executive Officer of the Company effective immediately.
ULURU INC. Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Nov 17, 7:00AM CST
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the third quarter ended September 30, 2015 and provided a review of its business activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter 2015
PR Newswire - Wed Nov 11, 9:29AM CST
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the third quarter ending September 30, 2015 financial results and to provide a general business update on November 17, 2015 at 9:00 a.m. Eastern Time.
Global Collagens Pipeline Review 2015 Now Available
M2 - Thu Oct 08, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4tfqz7/collagens) has announced the addition of the "Collagens - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Collagens pipeline products. Scope - Extensive coverage of the Collagens under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Collagens and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Collagens - Pipeline Products under Development by Companies 5 Collagens Companies and Product Overview 6 Collagens- Recent Developments 7 Appendix Companies Mentioned - Advanced Medical Solutions Group plc - AGAM Biological Products - Alliqua BioMedical, Inc. - botiss dental GmbH - CollPlant Ltd. - Conversion Energy Enterprises - Covalon Technologies Ltd. - EternoGen, LLC - Holista CollTech Limited - Innocoll Technologies Limited - Jellagen Pty Ltd - Kyeron BV - Medtronic plc - Nanotherapeutics, Inc. - PlasMedica Technologies Limited - Shire Plc - Taxus Cardium Pharmaceuticals Group Inc. - ULURU Inc. For more information visit http://www.researchandmarkets.com/research/4tfqz7/collagens
MDT: 86.01 (+0.35), SHPG: 200.60 (+4.11)
ULURU Inc. To Raise $1,550,000 In Private Placement
PR Newswire - Fri Sep 11, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the signing of a definitive agreement to sell an aggregate of 4,079,539 shares of its common stock at a price per share of $0.38 to a group of European investors, which is expected to result in gross proceeds of $1,550,225. Under the terms of the agreement, the Company is obligated to file a registration statement registering the re-sale of the purchased shares, and the transaction will close promptly following the effectiveness of the registration statement. Such registration statement is required to be filed with the Securities and Exchange Commission promptly and the Company will use its best efforts to have it declared effective at the earliest possible date. The net proceeds of the private placement after expenses is estimated to be approximately $1,350,000.
ULURU Inc. Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 17, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the second quarter ended June 30, 2015 and provided a review of its business activities.
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter 2015
PR Newswire - Wed Aug 05, 4:37PM CDT
ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ending June 30, 2015 financial results and to provide a general business update on August 17, 2015 at 9:00 a.m. Eastern Time.
ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors
PR Newswire - Tue Jul 28, 7:30AM CDT
ULURU Inc. (OTCQB: ULUR) announced today the schedule for the 2015 Annual Meeting of Stockholders and the appointment of Bradley J. Sacks to the Company's Board of Directors.
ULURU Inc. Announces Interim Pharmacoeconomic Data
PR Newswire - Tue Jun 09, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) announced today interim results of a pharmacoeconomic evaluation being conducted in Europe.
ULURU Inc. Reports First Quarter 2015 Financial Results
PR Newswire - Mon May 18, 7:00AM CDT
ULURU Inc. (OTCQB: ULUR) today announced its financial results for the first quarter ended March 31, 2015 and provided a review of its operating activities.
ULURU Inc. Announces The Acquisition Of Altrazeal Trading GmbH
PR Newswire - Thu May 14, 8:35AM CDT
ULURU Inc. (OTCQB: ULUR) announced it will be acquiring the 75% ownership of Altrazeal Trading GmbH not currently owned by the Company. The company was granted the option pursuant to a Shareholders Agreement dated January 11, 2012, to acquire the remaining ownership for a predetermined valuation. Altrazeal Trading GmbH was established to commercialize Altrazeal, our proprietary wound care product, in Europe, the Middle East, and Australia/New Zealand.
(0)
(0)Scroll down for more posts ▼